US Patent 10472424 Treatment with anti-PCSK9 antibodies
Patent 10472424 was granted and assigned to Pfizer Limited on November, 2019 by the United States Patent and Trademark Office.
All edits
The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (LDL-C) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, preferably at or below 10 mg/dL.
US Patent 10472424 Treatment with anti-PCSK9 antibodies
Find more entities like US Patent 10472424 Treatment with anti-PCSK9 antibodies
